Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05224258 · ClinicalTrials.gov registry record · NA

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

A NA study, sponsored by Medtronic MiniMed.

Completed
Registry status
NA
Development phase
240
Enrollment target

NCT05224258: Completed NA study, sponsored by Medtronic MiniMed.

NCT05224258 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05224258, a NA study, has completed, sponsored by Medtronic MiniMed.

COMPLETED
Registry status
NA
Development phase
240 participants
Enrollment target

Study Summary

This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.

Primary Outcome

The overall mean change in HbA1c from baseline to end of 3-month study period. Non-inferiority test.

Interventions

  • DEVICE MiniMed 780G System

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2022-03-17
Est. Completion 2024-06-21
Phase NA
Medtronic MiniMed

29 total trials

What the finished NCT05224258 record still lists

NCT05224258 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which MiniMed 780G System is the first listed.

NCT05224258 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05224258 about?

NCT05224258 is a clinical study titled "Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®". This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.

What is the current status of trial NCT05224258?

This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2022-03-17. Estimated completion is 2024-06-21.

What interventions are being tested in trial NCT05224258?

The interventions under investigation include: MiniMed 780G System (DEVICE).

Who is sponsoring clinical trial NCT05224258?

This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05224258's enrollment target sits among peer trials

240 440th of 2000 higher than 1,542 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05224258, the US trial registry maintained by the National Library of Medicine. NCT05224258 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.